Biostem Technologies, Inc. (NASDAQ:BSEM – Get Free Report) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 119,203 shares, a decline of 78.5% from the August 15th total of 554,233 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average trading volume of 89,169 shares, the days-to-cover ratio is presently 1.3 days.
Analyst Ratings Changes
BSEM has been the subject of a number of recent analyst reports. Wall Street Zen raised Biostem Technologies to a “sell” rating in a report on Saturday, September 5th. Weiss Ratings started coverage on Biostem Technologies in a research note on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biostem Technologies currently has an average rating of “Sell”.
Read Our Latest Research Report on Biostem Technologies
Biostem Technologies Stock Up 3.1%
Biostem Technologies Company Profile
BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.
Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.
See Also
- Five stocks we like better than Biostem Technologies
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
- Nasdaq’s $100 Million Kraken Bet Prepares It for a Market That Never Closes
- Copper’s Record Rally Highlights a Deeper Supply Problem
Receive News & Ratings for Biostem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
